Whitepaper: Accelerating Alzheimer’s Therapy Innovation: The Power of Blood-Based Biomarkers
The escalating global challenge of Alzheimer's Disease (AD) demands new approaches to detection, diagnosis, and treatment. Dr Michael K. Racke, Medical Director of Neurology at Quest Diagnostics, will delve into recent advancements in the AD diagnostic landscape.
Discover how blood-based biomarkers are reshaping AD therapy by:
- Simplifying Diagnosis: Uncover the non-invasive procedures that are making early detection more accessible.
- Promoting Early Intervention: Explore how blood-based tests enable proactive measures, even before symptoms appear.
- Facilitating Longitudinal Monitoring: Learn how continuous tracking of disease progression paves the way for personalized therapeutic strategies.
- Boosting Cost-effectiveness: Find out how this accessible approach is more economically viable, promoting widespread adoption.
Together, we can embrace the power of blood-based biomarkers, break down barriers, and usher in a new era of hope and healing.
The journey towards a world without Alzheimer's is filled with complexities, but the path ahead is bright with possibilities. Your partnership and engagement in this mission are vital.
To learn more about our approach and the exciting developments in blood-based biomarkers for Alzheimer's, download the full whitepaper here.
About the Author
-
Medical Director of Neurology, Quest Diagnostics
Michael K Racke, MD, is Medical Director of Neurology at Quest Diagnostics. His prior research was on the pathogenesis of multiple sclerosis, with early research and preclinical work leading to novel
treatments including anti-CD20 monoclonal antibody treatment for progressive multiple sclerosis.
Dr Racke’s training includes an MD from University of Medicine and Dentistry of New Jersey, neurology training at Emory University, and a neuroimmunology fellowship at the National Institutes of Health. He has served on the faculties of Washington University, University of Texas Southwestern Medical Center, and The Ohio State University School of Medicine.
Dr Racke has been on many advisory committees and boards, including those of the National Multiple Sclerosis Society, National Institutes of Health, American Committee on Treatment and Research in Multiple Sclerosis, and Consortium of Multiple Sclerosis Centers. He has also served on several editorial boards, including JAMA Neurology and Annals of Neurology, and as editor-in-chief of the Journal of Neuroimmunology.
-
Connecting life sciences to Quest Diagnostics
When you choose us as your partner in Pharma Services, you get more than lab testing. Access the reach, expertise, and renowned quality of Quest Diagnostics for every milestone of your program—from R&D consulting through clinical trials, companion diagnostic development, commercialization, and post-launch surveillance. Together we have the power to deliver better outcomes.
